Quantifying atherogenic lipoproteins for lipid-lowering strategies: Consensus-based recommendations from EAS and EFLM

The joint consensus panel of the European Atherosclerosis Society (EAS) and the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) recently addressed present and future challenges in the laboratory diagnostics of atherogenic lipoproteins. Total cholesterol, triglycerides, HDL c...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Atherosclerosis 2020-02, Vol.294, p.46-61
Hauptverfasser:	Nordestgaard, Børge G., Langlois, Michel R., Langsted, Anne, Chapman, M. John, Aakre, Kristin M., Baum, Hannsjörg, Borén, Jan, Bruckert, Eric, Catapano, Alberico, Cobbaert, Christa, Collinson, Paul, Descamps, Olivier S., Duff, Christopher J., von Eckardstein, Arnold, Hammerer-Lercher, Angelika, Kamstrup, Pia R., Kolovou, Genovefa, Kronenberg, Florian, Mora, Samia, Pulkki, Kari, Remaley, Alan T., Rifai, Nader, Ros, Emilio, Stankovic, Sanja, Stavljenic-Rukavina, Ana, Sypniewska, Grazyna, Watts, Gerald F., Wiklund, Olov, Laitinen, Päivi
Format:	Artikel
Sprache:	eng
Schlagworte:	Apolipoprotein B Atherosclerosis - etiology Atherosclerosis - prevention & control Atherosclerotic cardiovascular disease Humans Hyperlipidemias - complications Hyperlipidemias - drug therapy Hypolipidemic Agents - therapeutic use LDL cholesterol Life Sciences Lipoprotein(a) Lipoproteins - physiology non-HDL cholesterol Remnant cholesterol
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!